ISRG — Intuitive Surgical, Inc.

Is ISRG overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Neutral As of October 3, 2026

Intuitive Surgical, Inc. (ISRG) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $391.95. The rating moved from Overbought to Neutral on October 2, 2026.

AI analysis

Intuitive Surgical benefits from a durable franchise in robotic surgery with a large installed base, recurring consumable revenue and steady free cash flow that support ongoing investment and optionality. Near-term sentiment is cautious given broader market risk-off and elective procedure sensitivity, but medium-term catalysts include product refreshes, sustained procedure adoption and geographic expansion. Key risks include payer reimbursement pressure, competition, regulatory outcomes and cyclicality in hospital capital spending.

Key factors

  • Clear market leadership in robotic-assisted surgery with a large installed base and high switching costs for hospitals
  • Recurring revenue model from instruments, accessories and service contracts supports predictable high-margin cash flow
  • Ongoing product pipeline and innovation (platform upgrades, expanded indications, and procedural breadth) supports long-term procedure growth
  • Strong balance sheet and free cash flow generation enable R&D investment, capital returns and strategic M&A if needed
  • Global procedure volume growth and aging demographic tailwinds support secular demand for minimally invasive surgical technologies
  • Pricing power with hospital customers due to integrated ecosystem (system + consumables + service)
  • Resilience vs. cyclicality: procedure volumes historically recover post-economic softness, supporting revenue durability

Risks

  • Reimbursement and payer pressure (including indirect effects from Medicare Advantage and cost-containment initiatives) that could limit hospital adoption or pricing
  • Stronger competition from large medtech peers and emerging entrants offering alternative robotic or assisted-surgery platforms
  • Regulatory or safety-related setbacks, recalls, or negative clinical outcomes that could slow adoption or invite litigation
  • Macro-driven declines in elective procedures during risk-off periods or slower hospital capital spending that delay system purchases
  • Concentration risk in consumables revenue tied to installed base growth; slower system placements limit long-term consumable growth
  • Supply chain disruptions or component shortages that impact production and deliveries
  • Potential for increased government scrutiny on device pricing or hospital procurement practices

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ISRG — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.